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The goal of this research was to elucidate the relationship between WHO 2016 molecular classifications of newly
diagnosed, nonenhancing lower grade gliomas (LrGG), tissue sample histopathology, and magnetic resonance
(MR) parameters derived from diffusion, perfusion, and 1H spectroscopic imaging from the tissue sample
locations and the entire tumor. A total of 135 patients were scanned prior to initial surgery, with tumor cellularity
scores obtained from 88 image-guided tissue samples. MR parameters were obtained from corresponding sample
locations, and histograms of normalized MR parameters within the T2 fluid-attenuated inversion recovery lesion
were analyzed in order to evaluate differences between subgroups. For tissue samples, higher tumor scores were
related to increased normalized apparent diffusion coefficient (nADC), lower fractional anisotropy (nFA), lower
cerebral blood volume (nCBV), higher choline (nCho), and lower N-acetylaspartate (nNAA). Within the T2 lesion,
higher tumor grade was associated with higher nADC, lower nFA, and higher Cho to NAA index. Pathological
analysis confirmed that diffusion and metabolic parameters increased and perfusion decreased with tumor
cellularity. This information can be used to select targets for tissue sampling and to aid in making decisions about
treating residual disease.
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liomas are the most common type of primary brain cancer in adults
d are classified by the WHO 2016 classification scheme as either
ioblastoma (GBM, grade IV) or lower-grade (grades II and III)
ffuse gliomas. These lower-grade gliomas (LrGG) are further
fined as astrocytomas (isocitrate dehydrogenase (IDH)–mutant or
H wild-type) or as oligodendrogliomas (IDH-mutant with
romosome 1p/19q codeletion) [1]. While overall survival for
rGG has lengthened to 5 to 20 years due to advances in diagnosis
d therapy, the disease remains almost inevitably fatal [2]. While the
itial step in treatment is surgical resection, at the current time, there
no definitive standard of care for subsequent treatment [3]. The
ck of consensus stems partly from the difficulty in predictingognosis and defining response to the various therapeutic approaches
r individual patients.
Although the WHO 2016 classification is obtained by analyzing
ssue samples that are acquired at the time of initial surgery, there is
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942 Newly Diagnosed, Nonenhancing Lower-Grade Gliomas Luks et al. Translational Oncology Vol. 11, No. 4, 2018ill considerable variability in the course of the disease for individual
tients [4]. The identification of imaging markers that can guide
rsonalized treatment is especially important. Multiparametric MR
aminations that integrate anatomic imaging with diffusion (DWI),
rfusion (PWI), and spectroscopic (MRSI) imaging have been
veloped to provide a more objective and comprehensive evaluation
the structural, physiological, and metabolic properties of gliomas.
hese advanced imaging parameters are particularly important for
eatment planning in patients newly diagnosed as having LrGG
cause the majority of them have no gadolinium contrast
hancement on T1-weighted anatomical imaging and the definition
tumor burden relies upon the evaluation of regions with
perintensity on T2-weighted images.
The goal of this study was to elucidate the relationship between
olecular classifications of LrGG, histological characteristics, and
R parameters. The population comprised 135 patients with newly
agnosed, nonenhancing LrGG, who were scanned before their
itial surgery. Image-guided tissue samples were collected in a subset
patients and analyzed to relate their molecular characteristics and
thology to imaging characteristics.
ethods
CSF Institutional Review Board approval was obtained to study
tients with a suspected pathological diagnosis of a WHO grade II or
I glioma without gadolinium contrast enhancement on T1-
eighted MR images. Patients were recruited immediately prior to
rgical resection and gave written informed consent.
R Acquisition
MR examinations were performed on 1.5-T or 3-T scanners (GE
ealthcare Technologies) using an eight-channel phased-array headcoil
RI Devices). Standard anatomical imaging included T2-weighted
id-attenuated inversion recovery (FLAIR), fast spin echo, and T1-
eighted pre- and postgadolinium sequences. Diffusion-weighted
ages (DWI) were obtained in the axial plane with six gradient
rections [repetition time (TR)/echo time (TE) = 1000/108
illiseconds, voxel size = 1.7 × 1.7 × 3 mm, b = 1000 s/mm]. Dynamic
sceptibility contrast-enhanced perfusion-weighted images (PWI)
tained following a 5-ml/s bolus injection of 0.1 mmol/kg body
eight gadolinium diethyltriamine pentaacetic acid and were acquired
ing a series of T2*-weighted echo-planar images [TR/TE/flip angle =
50-1500/35-54 milliseconds/30°-35°, 128 × 128 matrix, slice
ickness = 3-5 mm, 7-15 slices with 60-80 time points] before,
ring, and after arrival of the contrast agent. Lactate-edited 3D proton
R spectroscopic imaging data were obtained using point-resolved
ectroscopic selection or volume localization and very selective
turation pulses for lipid signal suppression [excited volume = 80 ×
× 40 mm, TR/TE = 1104/144 milliseconds, overpress factor = 1.5,
ld of view = 16 × 16 × 16 cm, nominal voxel size = 1 × 1 × 1 cm,
back echo-planar readout gradient in the SI direction, 988 Hz sweep
idth and 712 dwell points] [5].
R Data Processing
The anatomic, diffusion, perfusion, and spectroscopic images were
igned to the T1 postcontrast image using FMRIB's Linear Image
egistration Tool [6,7] (http://fsl.fmrib.ox.ac.uk). Each ROI was
fined by a single investigator (either the first or second author), with
e guidance of UCSF neuroradiologists. The T2 lesion ROI was
fined using semiautomated software (BrainLAB Systems, Munich)include all T2 FLAIR hyperintensity, relative to the surrounding
rmal tissue. These T2 lesion ROIs are 3D volumetric ROIs that
clude all T2 FLAIR hyperintensity on all slices. (Figure 1). When
ssue samples were available, 5-mm–diameter spherical ROIs
ntered on the spatial coordinates recorded using the surgical
vigation software (BrainLAB,Munich) were generated. The accuracy
the registration of the biopsy location to the T1 image within the
rainlab system has been documented previously [8], particularly by
araskevopoulos et al. [9], who assessed this accuracy using a viscoelastic
antom to replicate tissue shift. They reported that biopsy location was
curate within 1.5 mm. A 5-mm–diameter ROI was chosen to balance
e potential biopsy localization error and the need to restrict the ROI to
mediate vicinity of the sampled tissue.
For DWI data, a previously published algorithm [10] was applied to
timate relevant DWI parameters and normalize between field
rengths using estimates from normal-appearing brain tissue. In
der to provide metrics that described regions with abnormal
tensities, the voxel values for ADC and FAmaps were first normalized
the mode of intensities in normal-appearing brain tissue (calculated
ross the entire cerebrum, excluding the T2 lesion ROI). Percentiles
0th, 50th, 90th) were then calculated from histograms of normalized
tensities withinT2 lesionROIs. ADC and FA are typically interpreted
measures of tissue microarchitecture and cellularity in gliomas
1–14]. By measuring normalized ADC (nADC) and normalized FA
FA) in the voxels with the highest and lowest diffusion values across
e tumor, it was possible to explore whether the presence of some
gions of very high or very low diffusion had a significant relationship
molecular characteristics and pathology.
For PWI data, cerebral blood volume (CBV) and peak height (PH)
ere calculated for each voxel using software developed in our research
oup [15,16]. The T2* signal-intensity time curves acquired during
e first pass of the gadolinium bolus were converted to change in the
laxation rate (DR2*) and resampled to match the spatial resolution of
e anatomic image series. PHwas defined as themaximumDR2* value
the first-pass curve. CBV maps were calculated on a voxel-by-voxel
sis utilizing a modified gamma-variate function that takes into
count leakage of the contrast agent. PH is a simpler, nonparametric
proach to characterizing the DR2* curve. Like CBV, PH is predictive
the relative contribution of simple vascular density in glioma [17].
his parameter requiresminimal computational time for postprocessing
e data, which makes them a common choice for use in the clinic. The
BV and PH intensities from the T2 lesion and tissue sample ROIs
ere normalized by values within normal brain [18,19].
For MRSI data, the methods used for reconstruction and
stprocessing are fully automated and have been described in
evious publications [20–22]. In brief, the start point was the raw
ta file obtained from the lactate edited MRSI sequence. This
mprised interleaved acquisitions (or cycles) obtained with
diofrequency pulses that modulated the phase of the lactate peak,
ith each cycle having eight channels of data corresponding to the
ultiple receiver coils. The k-space time domain data for each cycle
d channel were first filtered with a 4-Hz exponential function in the
me domain, zero filled to 1024 points, and Fourier transformed
produce a k-space array of spectra. The next step was to apply the
space Fourier transforms to produce 3D spatial arrays of spectral
ta, followed by combination using in-house–developed software
at weights the data by coil sensitivities estimated from low-
solution proton density–weighted images [22]. Additional phase
rrections were applied in the SI dimension to account for the
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2 4
Figure 1. Example of ADC map, T1 contrast (+Gd), CBV perfusion map, T2 FLAIR, and MRSI data from a single LrGG patient. The blue
outline on the T1 + Gd image and MRSI grid indicate the T2 lesion ROI. On the CBV map, pink regions reflect higher CBV. The MRSI grid
indicates the spectra and CNI values from each voxel, and the color map superimposed on the T2 FLAIR image indicates voxels with
abnormally high CNI.
Translational Oncology Vol. 11, No. 4, 2018 Newly Diagnosed, Nonenhancing Lower-Grade Gliomas Luks et al. 943back echo-planar readout gradient [23]. The cycles were summed
produce an array of spectra containing choline, creatine, NAA, and
id and subtracted to produce an array of spectra containing lactate.
ectra were baseline subtracted and phase and frequency corrected
ing parameters estimated from the summed array. Metabolite levels
ere obtained by estimating peak heights and integrated areas from
e spectral arrays [20].
Peak heights and areas were determined from baseline-subtracted,
equency- and phase-corrected spectra on a voxel-by-voxel basis [24].
etabolite peak heights were normalized by median peak heights in
rmal brain for Cho and Cr (nCho and nCr), and normalized Lac,
ip, and LL (nLac, nLip, and nLL) were estimated by metabolite peak
ights divided by the median peak NAA intensity in normal brain.
he Cho signal reflects changes in membrane synthesis and turnover
sociated with cell proliferation and remodeling. NAA is a marker of
rmal brain tissue associated with the presence of actively
nctioning neurons. Lac is an end product of anaerobic metabolism
normal cells and aerobic glycolysis in cancer and reflects ischemia
d/or hypoxia. The Cr peak includes both creatine and phospho-
eatine and is indicative of cellular bioenergetic processes. The
oline-to-NAA index (CNI) is a z-score that reflects changes in the
lative levels of these two metabolites compared to normal brain
xels, and the choline-to-creatine (CCRI) index is defined in a
milar manner [25]. The metabolic lesion was defined as the region
ith CNI values greater than 2 (Figure 1). Cho, Cr, and NAA
tensities were normalized by their median value in voxels that had
en identified during the CNI calculation as being from normal
ain (nCho, nCr, and nNAA). Levels of Lac were normalized (nLac)
the median level of NAA from voxels within the selected volume
t outside of the CNIN 2 region.age-Guided Brain Tumor Tissue Sampling
Tissue sample targets were planned for a subset of the patients
sed on surgically accessible regions of both abnormally decreased
DC and abnormally increased ADC in order to sample a variety of
stopathology. Intraoperative navigation guided the neurosurgeons
these locations and was used to obtain a 3D screenshot of the actual
rget coordinates of the excised tissue sample. The neurosurgeons
quired tissue samples as early as safely possible in the surgical
ocedure and only from locations that had not yet experienced
gnificant tissue shift. To minimize any unnecessary risks to the
tient, no regions of normal-appearing brain were targeted. Samples
ere immediately fixed, processed, and embedded as previously
scribed [19].
umor Cellularity, Immunohistochemistry, and Fluorescence
Situ Hybridization (FISH) Determinations
For H&E-stained slides, a tumor score was given on the basis of the
ntribution of tumor cellularity to total cellularity. Scores of 0
noted neuropil without tumor; 1 indicated an infiltrating tumor
argin containing detectable, but not abundant, numbers of tumor
lls; 2 denoted a more cellular-infiltrated zone; 3 denoted highly
llular tumor with few non-neoplastic cells. Immunohistochemistry
r the IDH1 p.R132H mutation and FISH to assess 1p/19q
deletion status were performed as previously described [26,27].
HO 2016 Diagnostic Classification
Tumor grade and diagnostic subtype were determined by a board-
rtified neuropathologist. Subtype classification was based on the
16 WHO classification molecular and histological criteria [1].
GG were classified as either 1) oligodendrogliomas, IDH-mutant
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Table 1. Imaging Results from Tissue Sample ROIs by Tissue Sample Tumor Scores
Group Number of Samples with DWI nADC nFA Number of Samples with PWI nCBV Number of Samples with MRSI nNAA nCho CNI
All samples 88 1.88 0.60 77 0.72 57 0.36 1.42 4.48
All samples vs tumor score (TS) 81 73 54
TS = 0 5 1.47 0.72 5 1.06 4 0.43 0.87 1.69
TS = 1 15 1.53 0.70 11 0.89 9 0.52 1.34 3.72
TS = 2 38 1.86 0.64 38 0.71 24 0.44 1.69 5.45
TS = 3 23 2.17 0.47 19 0.53 17 0.21 1.33 4.01
F value 6.62 3.97 3.99 3.55 2.98 ns
P value .0005 .012 .011 .021 .048
IDH-mutant astrocytoma 46 39 30
TS = 0 0 0 0
TS = 1 9 1.58 0.78 5 0.97 6 0.49 1.47 4.37
TS = 2 24 1.88 0.58 25 0.62 14 0.40 1.64 5.38
TS = 3 13 2.35 0.43 9 0.52 10 0.25 1.06 3.35
F value 8.24 5.93 3.04 ns ns ns
P value .0009 .005 .06
1p/19q co-deleted oligodendroglioma 25 22 12
TS = 0 3 1.43 0.76 5 1.06 3 0.44 0.90 2.07
TS = 1 5 1.45 0.60 4 0.95 2 0.63 1.28 3.16
TS = 2 9 1.66 0.79 6 0.90 3 0.72 2.49 6.77
TS = 3 8 1.98 0.53 7 0.60 4 0.21 1.39 5.70
F value 3.67 ns ns ns ns ns
P value .029
Imaging values are the group averages of the median imaging values.
Significant after Benjamini-Hochberg false discovery rate correction for multiple comparisons.
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944 Newly Diagnosed, Nonenhancing Lower-Grade Gliomas Luks et al. Translational Oncology Vol. 11, No. 4, 2018d 1p/19q-codeleted; 2) astrocytoma, IDH-mutant (if they were not
/19q co-deleted and expressed IDH1 R132H mutant protein); or
astrocytoma, not otherwise specified (NOS) (if they had
trocytoma histology and IDH status was unknown or if the
H1 R132H IHC stain was negative). Note that the IDH wild-type
atus was not confirmed with IDH1 and IDH2 codon sequencing,
d hence, the IDH1 R132H immunonegative astrocytomas were
cluded in the astrocytoma, NOS category. Grade determinations
ere performed utilizing WHO 2016 criteria. For astrocytoma,
evated mitotic index was the main determinant for distinguishing
e grade II from III, and microvascular proliferation and necrosis
ere not present by definition. For anaplastic oligodendroglioma,
H-mutant and 1p/19q-codeleted, WHO grade III, brisk mitotic
tivity (N/=6 per 10 high-power fields) or conspicuous microvascular
oliferation was required.
tatistical Analysis
The relationship between histological and molecular tumor character-
tics (tumor score, grade, and WHO 2016 subgroup) and MRI
rameters was assessed with repeated-measures analyses of varianceble 2. Imaging Results from Tissue Sample ROIs between and within 1p/19q Co-Deleted Oligodend
oup Number of Samples with DWI nADC nFA Numbe
ade II 52 1.73 .63 44
ade III 36 2.11 .54 33
value 10.73 ns
value .002
H-mutant astrocytoma
ade II 22 1.75 0.64 17
ade III 28 2.15 0.50 24
value 8.80 4.34
value .005 .043
H-mutant astrocytoma 50 1.98 0.56 41
/19q co-deleted oligodendroglioma 28 1.70 0.64 23
value 5.9 ns
value .018
aging result values are the group averages of the median imaging values.
Significant after Benjamini-Hochberg false discovery rate correction for multiple comparisons.sing JMP Pro 13.0, SAS Institute Inc.). The cutoff for defining a
gnificant result in this exploratory study was aP value of .05. Effects that
main significant using a Benjamini-Hochberg false discovery rate [28]
rrection for multiple comparisons are indicated in Tables 1-3.
gnificant main effects for variables with three or more levels were
llowed up with pairwise Tukey-Kramer HSD post hoc tests.esults
atient Characteristics
Of the 135 patients with lower-grade glioma enrolled in this study,
were characterized as grade II and 46 as grade III. The median age
the population was 41 (interquartile range = 31-49 years), and 64
7%) were female. Evaluation of postoperative imaging indicated
at 44 (33%) patients received gross total resections, 88 (65%) had
btotal resections, and 3 (2%) had biopsies only. There were 63
tients with IDH-mutant astrocytoma, 39 patients with IDH-
utant, 1p/19q co-deleted oligodendroglioma, 26 astrocytomas that
ere IDH negative by immunohistochemistry, and 7 astrocytomasroglioma and IDH-Mutant Astrocytoma Subgroups
r of Samples with PWI nCBV Number of Samples with MRSI nNAA nCho CNI
.82 37 .37 1.43 4.40
.59 20 .34 1.39 4.64
4.97 ns ns ns
.031
0.68 17 0.32 1.30 4.19
0.59 15 0.35 1.47 4.71
ns ns ns ns
0.63 32 0.33 1.38 4.44
0.89 13 0.48 1.60 4.83
4.08 ns ns ns
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fo
19
gr
pr
T
ca
Im
va
w
T
an
lo
m
68
tu
(m
de
3)
ob
w
su
m
va
no
(s
Table 3. Imaging Results from T2 Lesion ROIs between and within 1p/19q Co-Deleted Oligodendroglioma and IDH-Mutant Astrocytoma Subgroups
Group Comparison Diffusion Parameters MRSI Parameters
All patients Grade II vs grade III 71 vs 39 patients
nADC: 10% (P = .039)
nFA: 90% (P = .023)
60 vs 33 patients
CNI (P = .015 )
IDH-mutant astrocytoma Grade II vs grade III 20 vs 36 patients
ns
23 vs 23 patients
nCHO (P = .041)
IDH-mutant astrocytoma
vs
1p/19q co-deleted oligodendroglioma
All patients 56 vs 29 patients
nADC: 10%, median, 90% (P = .0006 , .0001 , .0001 )
nFA: 10%, median (P = .006 , .015 )
46 vs 28 patients
CNI, nCHO, CCRI (P = .01, .032, .012)
nLAC (P = .015)
Grade II only 30 vs 29 patients
nADC: 10%, median, 90% (P = .045, .0001 , .0001 )
nFA: 10%, median (P = .029, .046)
23 vs 28 patients
ns
Significant after Benjamini-Hochberg false discovery rate correction for multiple comparisons.
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q co-deleted oligodendroglioma were classified as being WHO
ade II. Confirmed locations for image-guided tissue samples on
esurgical MRIs were acquired for 88 samples from 45 patients.
able 1 indicates the number of samples from patients in each
tegory of the WHO 2016 classification.
aging Values in Tissue Sample ROIs Versus Tumor Score
There were 81 samples with tumor scores and diffusion parameter
lues, 73 with tumor scores and perfusion parameter values, and 54
ith tumor scores and spectroscopic parameter values (see Table 1).
he overall median nADC, nCho, and CNI were higher (1.88, 1.42,
d 4.48) than normal brain, with the nFA, nCBV, and nFAA being
wer (0.60, 0.72, and 0.36) than normal brain. In all cases, theM
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Figure 3. (A) Median nADC within tissue sample ROIs, (B) nFA within tissue sample ROIs, (C) median CNI within T2/CNI N2 lesion ROIs,
and (D) median CCRI values within T2/CNI N2 lesion ROIs for IDH mutant astrocytoma (AS IDH+) and 1p/19q co-deleted
oligodendroglioma (OD) LrGG patients.
946 Newly Diagnosed, Nonenhancing Lower-Grade Gliomas Luks et al. Translational Oncology Vol. 11, No. 4, 2018For the samples with positive tumor score that had perfusion
lues, the median nCBV significantly decreased with increasing score
.89 to 0.53 for tumor scores of 1 to 3) (see Table 1). The same
nge of values and trends was observed when the analysis was
stricted within each molecular subgroup. Within samples with
H-mutant astrocytoma, nCBV showed a trend towards lower
lues with higher tumor scores (P = .06), with significantly lower
BV values for tumor scores of 2 and 3 than 1 (see Figure 2A).
ithin samples with 1p19q co-deleted oligodendroglioma, the
lationship between tumor score and nCBV did not reach
gnificance.
For the spectroscopic data, there was a significant decrease in
AA with tumor score (0.52 to 0.21 for tumor scores of 1 to 3) (see
able 1). The nCho and CNI were both elevated in samples with
sitive tumor score, but the highest nCho and CNI values were in
mples with tumor scores of 2. A similar pattern was observed in
bgroups of samples based upon the WHO 2016 criteria, but the
lationships to tumor score were not significant.
aging Values in Tissue Sample ROIs Versus Grade and
HO 2016 Subgroup
For lesions characterized as grade II, there were 52 samples with
ffusion, 44 samples with perfusion, and 37 samples with
ectroscopic values (see Table 2). The corresponding numbers of
mples from grade III lesions were 36, 33, and 20, respectively.
hen values from all relevant samples were considered, the only
rameters that were significantly different between grades were the
edian nADC (1.73 for grade II and 2.11 for grade III, P = .002) andedian nCBV (0.82 for grade II and 0.59 for grade III, P = .031).
hen the analysis was restricted to the IDH-mutant astrocytomas,
ly the median nADC (1.75 vs 2.15, P = .005) and the median nFA
.64 vs 0.50, P = .043) were significantly different between samples
om grade II and III lesions (see Figure 2B). When all samples from
H-mutant astrocytoma were compared with those from 1p19q co-
leted oligodendroglioma, the only parameters that were signifi-
ntly different were the median nADC (1.98 vs 1.70, P = .018, see
igure 3A) and the nCBV (0.63 vs 0.89, P = .022).
aging Values in Lesion Level ROIs Versus Grade and WHO
016 Subgroup
While none of the perfusion parameters within the T2 lesion ROIs
owed significant differences between grades and WHO 2016
bgroups, there were several findings for diffusion and spectroscopic
rameters (see Table 3). When comparing values for grade II lesions
rsus grade III lesions, there were significant differences detected in
e 10th percentile nADC (P = .039), the 90th percentile nFA (P =
23), and the median CNI (3.41 vs 3.92, P = .015, see Figure 2B).
ithin the IDH-mutant astrocytomas, there was a significant
fference in the median nCHO between grade II and grade III
sions but not in summary metrics from histograms of nADC
d nFA.
When comparing between WHO 2016 subgroups, there were
gnificant differences in the 10th percentile, median, and 90th
rcentile nADC and the 10th percentile and median nFA, as well as
the median CNI (see Figure 3C), nCho, CCrI (see Figure 3D), and
ac between the IDH-mutant astrocytomas and the 1p19q co-
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IDH-mutant astrocytomas that were characterized as grade II, the
DC and nFA metrics showed similar results, but there were no
gnificant findings for the spectroscopic parameters.
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stiscussion
he goal of this study was to provide information that could be used
interpreting diffusion, perfusion, and spectroscopic imaging data
om patients with newly diagnosed, nonenhancing LrGG. Deter-
ining how parameters derived from these advanced imaging
odalities vary between and within the WHO 2016 molecular
bgroups is critical for evaluating prognosis and resolving ambigu-
ies associated with conventional anatomic images. By obtaining
aging data at the presurgical examination and acquiring image-
ided tissue samples from a subset of the patients, we were able to
ake direct comparisons of in vivo parameters with molecular and
stological characteristics. Our findings have highlighted the
mplementary nature of these advanced imaging modalities and
tected significant differences in parameter values between molec-
ar subgroups of LrGG at both the tissue sample and whole
sion level.
The parameters that showed the largest number of significant
dings and emphasized the potential for using DWI in evaluating
rGG were the nADC and nFA. Of particular interest in this case was
at higher nADC and lower nFA were associated with higher tumor
ores and grade III rather than grade II histology. This is in contrast
previous reports, which indicated that lower ADC was associated
ith worse clinical outcomes for patients with GBM and could be
terpreted as a surrogate marker of tumor cellularity [11,13]. Our
sults suggest that in these newly diagnosed, nonenhancing LrGG,
e values of nADC and nFA are dominated by tumor infiltration
using disruption of neuronal, axonal, and glia microstructure rather
an by changes due to abnormal cellularity [29]. The association of
gher nADC with lesions that may have a worse prognosis is further
pported by the differences between the WHO 2016 subgroups, for
hich IDH-mutant astrocytomas have higher nADC than the 1p19q
-deleted oligodendrogliomas, both at the tissue sample and at the
hole lesion level. The values observed in this analysis were consistent
ith our previously published data [30], which were not specific to
olecular subgroups but did separate results based upon histological
sessments of astrocytoma versus oligodendroglioma. Of note is that
e previously observed lower nADC in regions of contrast
hancement in newly diagnosed grade III glioma relative to
nenhancing regions [31], and in a study of recurrent grade II
ioma, where a substantial number of the lesions had regions of
hancement, we found that lower nADC was associated with
alignant progression [32]. Taken together, this suggests that the
DC values evolve as a result of treatment and tumor progression so
at cellularity may ultimately become a more dominant factor.
The analysis of the PWI data from our study indicated that the
BV values in grade II and III glioma were less than in normal-
pearing white matter and decreased in samples with higher tumor
ore and grade. As was the case for parameters derived from the DWI
ta, these results are different from those obtained in prior studies of
tients with GBM, which indicate that lesions with higher nCBV
ve a worse prognosis [16]. It seems likely that these newly
agnosed, nonenhancing LrGG tumors have not yet caused a
gnificant change in angiogenesis and that the values observed areerefore more reflective of the disruption of normal microvascula-
re. The observation that the nCBV is significantly lower in tissue
mples from IDH-mutant astrocytomas than in 1p19q co-deleted
igodendroglioma is consistent with our prior study that compared
lues in grade II lesions based upon histological subtypes [30].
In contrast to results obtained from the analysis of parameters from
WI and PWI data, the pattern of relationships between MRSI
rameters, molecular characteristics, and pathology for this study
as consistent with those reported for patients with GBM [16,33,34].
issue samples with positive tumor scores had higher nCho and lower
AA than normal brain, and the CNI values in the intersection of
e T2 and metabolic lesions were significantly higher for grade III
rsus grade II. Of particular interest in evaluating the WHO 2016
bgroups is that the median CNI, CCRI, nCho, and nLac were all
gher in lesion ROIs for patients with IDH-mutant astrocytomas
mpared with those with 1p19q co-deleted oligodendroglioma.
iven that there were no significant differences in metabolite levels
hen the analysis was restricted to comparing the results from grade II
sions and given the results from our previous analysis of grade II
sions that was based upon histological subtypes [30], it appears that
is may be accounted for by the differences in metabolite levels
tween grades.
Because treatment decisions can be based on the histopathologic
alysis of surgical biopsies, the selection of intratumoral targets to
opsy can profoundly impact patient care. Our results indicate that
gions with increased nCHO and decreased nNAA have high tumor
llularity, whether they are in enhancing or nonenhancing regions
d across all grades of glioma [16,33,34]. Color overlays of the CNI
e particularly helpful in highlighting regions with abnormal levels of
ese metabolites and, because they represent a combined z-score, are
sier to interpret than maps of relative metabolite levels [25]. For
nenhancing lesions that are more likely to be LrGG, regions with
gher nADC and lower nFA may provide samples with a higher
action of tumor cells. The use of ADC color-coded histogram maps
9,33] may be helpful for targeting tissue samples from regions with
th high and low values in order to get a complete picture of the
mor and potentially target tumor regions with different molecular
aracteristics.
Other applications that are particularly critical for the ongoing
anagement of patients with glioma are assessing the spatial extent of
sidual tumor and monitoring changes in tumor properties that are
sociated with response to therapy and tumor progression. The
sults of this and our prior studies of LrGG [29,39,33,34] indicate
at there are differences in the values of nADC, nCBV, and
etabolic parameters between WHO 2016 subgroups, which should
considered in interpreting findings from serial examinations of
dividual patients. Whether changes in these in vivo imaging
rameters provide additional prognostic information is still under
vestigation, as this requires a long-term study of patient outcomes.
It is important to note limitations of the current study. One is that
e size of the tissue sample ROIs (5 mm) is considerably larger than
e size of the actual tissue samples, and despite efforts by the
rgeons to collect tissue samples early in the resection, the location
curacy can be further impacted by brain shift during surgery.
nother is that, because the sample sizes for some of the molecular
bgroups of LrGG was small, the comparative analysis was restricted
the two most common types (IDH-mutant astrocytomas and
19q co-deleted oligodendroglioma). Future studies will be
rengthened by the routine acquisition of molecular characteristics
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948 Newly Diagnosed, Nonenhancing Lower-Grade Gliomas Luks et al. Translational Oncology Vol. 11, No. 4, 2018r WHO 2016 classification by using sequencing to confirm IDH
ild-type status and through the evaluation of additional molecular
aracteristics, such as ATRX loss and telomerase reverse transcriptase
omoter mutations, which are emerging as important biomarkers for
rGG [35,36].
In conclusion, this study achieved its goal by highlighting
fferences in advanced imaging parameters between and within
olecular subgroups of patients with newly diagnosed, nonenhancing
rGG. Pathological analysis confirmed the interpretation of
ectroscopy, diffusion, and perfusion parameters relative to tumor
ore and histological characteristics. While the spectroscopy results
ere consistent with the metabolic pattern of malignant features
served in GBM, the nADC was higher and nCBV was lower in
gions with higher tumor score and histologic grade, which are the
verse of patterns observed in GBM. The findings of the study may
important for directing tissue sampling to more malignant regions
the T2 lesion, for making decisions about treating residual disease,
d for interpreting the results from serial MR examinations.
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